Dova Pharmaceuticals, Inc.

Equities

DOVA

US25985T1025

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-0.07%	+269.92%

2019	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag	CI
2019	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase	CI

Dova Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 06, 2019 at 07:14 am EDT

Dova Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was USD 3.516 million compared to USD 4.584 million a year ago. Operating loss was USD 16.929 million compared to USD 19.008 million a year ago. Net loss was USD 17.064 million compared to USD 19.657 million a year ago. Basic loss per share was USD 0.6 compared to USD 0.7 a year ago. For the half year, total revenue was USD 7.517 million compared to USD 4.584 million a year ago. Operating loss was USD 33.281 million compared to USD 32.685 million a year ago. Net loss was USD 33.443 million compared to USD 33.427 million a year ago. Basic loss per share was USD 1.18 compared to USD 1.22 a year ago.

Latest news about Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag	19-12-09	CI
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase	19-12-09	CI
Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	19-12-09	CI
Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia	19-12-05	CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index	19-11-13	CI
Dova Pharmaceuticals, Inc. Announces Executive Changes	19-11-12	CI
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.	19-11-11	CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index	19-11-11	CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index	19-11-11	CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index	19-11-11	CI
Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.	19-09-29	CI
Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019	19-08-06
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-06	CI
Dova Pharmaceuticals Announces Availability of DOPTELET in the United States for Treatment of Chronic Immune Thrombocytopenia	19-07-19	CI
Transcript : Dova Pharmaceuticals, Inc. - Special Call	19-06-27
Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET for Treatment of Chronic Immune Thrombocytopenia	19-06-27	CI
Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	19-06-25	CI
Transcript : Dova Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2019, May-20-2019 02:00 PM	19-05-20
Transcript : Dova Pharmaceuticals, Inc., Q1 2019 Earnings Call, May 07, 2019	19-05-07
Dova Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI
Dova Pharmaceuticals Receives Positive Opinion from CHMP for DOPTELET (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	19-04-29	CI
Transcript : Dova Pharmaceuticals, Inc., Q4 2018 Earnings Call, Mar 05, 2019	19-03-05
Dova Pharmaceuticals, Inc. Announces Executive Appointments	19-03-05	CI
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-05	CI

Chart Dova Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Dova Pharmaceuticals Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Companyâs initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Companyâs product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DOVA PHARMACEUTICALS, INC.	+269.92%	808M
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs